Dr. Larry Allen is the Co-Director of the Colorado Program for Patient Centered Decisions and a Professor of Medicine at the University of Colorado, Denver. Dr. Allen’s research helps patients navigate the difficult decisions regarding therapy options for end-stage heart failure. He authored an editorial for Circulation Heart Failure, entitled “Hashing It Out Over Cannabis: Moving Toward a Standard Guideline on Substance Use for Cardiac Transplantation Eligibility That Includes Marijuana.” He has also given numerous debates on marijuana use in the transplant population. And he has helped guide the American Heart Association’s input on cannabis use and cardiovascular disease.
Use of marijuana and the varied forms of cannabis is steadily on the rise in the US as more states move to legalize the substance for both medicinal and recreational purposes. Transplant programs across the country also have a varied approach regarding pre and post-transplant use, as clear guidelines are lacking. Research into the effects of THC has been limited by its illegality at the federal level. Drug interactions warrant further evaluation and study. This review offers insight into the pre and post-transplant approach to marijuana and CBD oil use, drug interactions, and a review of proposed potential guidelines.